RAGE, vascular tone and vascular disease

Area of Science:

• Vascular Biology
• Inflammation
• Molecular Medicine

Background:

• Receptor for advanced glycation endproducts (RAGE) is increasingly implicated in vascular disease pathogenesis.
• RAGE is upregulated by pro-inflammatory transcription factor NF-kappaB activation due to stimuli like hyperglycemia and oxidized LDL.
• Ligand binding to RAGE amplifies inflammatory responses in the vasculature.

Purpose of the Study:

• To explore the central role of RAGE in vascular disease.
• To investigate the involvement of RAGE in pulmonary arterial hypertension (PAH).
• To assess the potential of RAGE antagonism as a therapeutic strategy.

Main Methods:

• Review of clinical and pre-clinical studies on RAGE.
• Analysis of RAGE upregulation mechanisms via NF-kappaB.
• Examination of RAGE ligand interactions (AGEs, S100 proteins) and downstream effects (ROS, NO bioavailability).
• Studies involving transgenic mice overexpressing RAGE ligands and RAGE antagonism in pulmonary arterial smooth muscle cells.

Main Results:

• RAGE activation by AGEs or S100 proteins generates reactive oxygen species (ROS) and further activates NF-kappaB.
• This process upregulates adhesion molecules and RAGE expression, promoting monocyte adhesion.
• ROS reduce nitric oxide (NO) bioavailability, impairing anti-inflammatory effects and vascular tone.
• RAGE signaling is implicated in PAH pathogenesis, with antagonism inhibiting pulmonary arterial smooth muscle cell proliferation and migration.

Conclusions:

• RAGE is a critical mediator of vascular inflammation and disease, including atherosclerosis and PAH.
• S100-RAGE signaling is vital for pulmonary vascular homeostasis and disease.
• Further research into RAGE antagonism holds promise for novel therapeutics and understanding vascular pathophysiology.